U.S. markets close in 4 hours 23 minutes
  • S&P 500

    3,603.21
    -35.14 (-0.97%)
     
  • Dow 30

    29,504.16
    -406.21 (-1.36%)
     
  • Nasdaq

    12,104.96
    -100.89 (-0.83%)
     
  • Russell 2000

    1,828.94
    -26.33 (-1.42%)
     
  • Crude Oil

    44.72
    -0.81 (-1.78%)
     
  • Gold

    1,782.50
    -5.60 (-0.31%)
     
  • Silver

    22.50
    -0.14 (-0.64%)
     
  • EUR/USD

    1.1952
    -0.0019 (-0.16%)
     
  • 10-Yr Bond

    0.8490
    +0.0070 (+0.83%)
     
  • GBP/USD

    1.3350
    +0.0036 (+0.27%)
     
  • USD/JPY

    104.3350
    +0.2500 (+0.24%)
     
  • BTC-USD

    19,435.40
    +1,083.96 (+5.91%)
     
  • CMC Crypto 200

    382.68
    +18.09 (+4.96%)
     
  • FTSE 100

    6,319.07
    -48.51 (-0.76%)
     
  • Nikkei 225

    26,433.62
    -211.09 (-0.79%)
     

New Strong Buy Stocks for January 2nd

Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today:

Builders FirstSource, Inc. (BLDR): This company that manufactures and supplies building materials has witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.9% over the last 60 days.

Builders FirstSource, Inc. Price and Consensus

 

Builders FirstSource, Inc. Price and Consensus
Builders FirstSource, Inc. Price and Consensus

Builders FirstSource, Inc. price-consensus-chart | Builders FirstSource, Inc. Quote

HomeStreet, Inc. (HMST): This company that provides commercial and consumer banking services has witnessed the Zacks Consensus Estimate for its current year earnings increasing 2.7% over the last 60 days.

HomeStreet, Inc. Price and Consensus

 

HomeStreet, Inc. Price and Consensus
HomeStreet, Inc. Price and Consensus

HomeStreet, Inc. price-consensus-chart | HomeStreet, Inc. Quote

Alexion Pharmaceuticals, Inc. (ALXN): This company that develops and commercializes various therapeutic products has witnessed the Zacks Consensus Estimate for its current year earnings increasing 4% over the last 90 days.

Alexion Pharmaceuticals, Inc. Price and Consensus

 

Alexion Pharmaceuticals, Inc. Price and Consensus
Alexion Pharmaceuticals, Inc. Price and Consensus

Alexion Pharmaceuticals, Inc. price-consensus-chart | Alexion Pharmaceuticals, Inc. Quote

ManTech International Corporation (MANT): This company that provides technology solutions and services has witnessed the Zacks Consensus Estimate for its current year earnings increasing 1.3% over the last 60 days.

ManTech International Corporation Price and Consensus

 

ManTech International Corporation Price and Consensus
ManTech International Corporation Price and Consensus

ManTech International Corporation price-consensus-chart | ManTech International Corporation Quote

PCTEL, Inc. (PCTI): This company that delivers performance critical telecom solutions has witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.3% over the last 60 days.

PCTEL, Inc. Price and Consensus

 

PCTEL, Inc. Price and Consensus
PCTEL, Inc. Price and Consensus

PCTEL, Inc. price-consensus-chart | PCTEL, Inc. Quote

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”

Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.6% per year. So be sure to give these hand-picked 7 your immediate attention.

See 7 handpicked stocks now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
PCTEL, Inc. (PCTI) : Free Stock Analysis Report
 
ManTech International Corporation (MANT) : Free Stock Analysis Report
 
HomeStreet, Inc. (HMST) : Free Stock Analysis Report
 
Builders FirstSource, Inc. (BLDR) : Free Stock Analysis Report
 
Alexion Pharmaceuticals, Inc. (ALXN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research